Thomas Jorg Heinrich Mehrling Purchases 17,000 Shares of Helix BioPharma Corp. (TSE:HBP) Stock

Key Points

• Thomas Jorg Heinrich Mehrling, a senior officer at Helix BioPharma Corp, purchased 17,000 shares at an average price of C$1.01, totaling C$17,170.00.
• Helix BioPharma's stock price remained stable at C$1.06 during mid-day trading, with a market capitalization of C$56.20 million.
• The company specializes in cancer drug development, focusing on immuno-oncology therapies based on proprietary technology.

Helix BioPharma Corp. (TSE:HBP - ) Senior Officer Thomas Jorg Heinrich Mehrling acquired 17,000 shares of the stock in a transaction that occurred on Monday, July 21st. The shares were bought at an average price of C$1.01 per share, with a total value of C$17,170.00.

Helix BioPharma Price Performance

Helix BioPharma stock remained flat at C$1.06 during mid-day trading on Tuesday. 6,300 shares of the company's stock traded hands, compared to its average volume of 4,956. The firm has a market capitalization of C$56.20 million, a PE ratio of -1.11 and a beta of -0.84. Helix BioPharma Corp. has a 12-month low of C$0.50 and a 12-month high of C$1.34. The firm's fifty day simple moving average is C$0.95 and its two-hundred day simple moving average is C$0.91.

Helix BioPharma Company Profile

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.